Jens Bedke
Impact in
- Pulmonary and Respiratory Medicine top 0.1%
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Renal cell carcinoma treatment 105
- Prostate Cancer Diagnosis and Treatment 24
- Prostate Cancer Treatment and Research 14
- Oncology 63
- Cancer Immunotherapy and Biomarkers 40
- Co-authors
- Arnulf Stenzl (142 shared papers)Stephan Kruck (70 shared papers)Jörg Hennenlotter (44 shared papers)Thomas Powles (10 shared papers)Steffen Rausch (65 shared papers)Elizabeth R. Plimack (5 shared papers)Axel Bex (13 shared papers)Bastian Amend (31 shared papers)
- Journals
- World Journal of Urology (28 papers)Annals of Oncology (24 papers)European Urology (23 papers)British Journal of Urology (13 papers)The Lancet Oncology (12 papers)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Jens Bedke
294 papers receiving 19.6k citations
Jens Bedke's Hit Papers
Peers
Comparison fields: 5 of 137
- Pulmonary and Respiratory Medicine 9.5k
- Oncology 6.3k
- Cancer Research 2.6k
- Surgery 4.9k
- Immunology 1.6k
Countries citing papers authored by Jens Bedke
This map shows the geographic impact of Jens Bedke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Bedke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Bedke more than expected).
Fields of papers citing papers by Jens Bedke
This network shows the impact of papers produced by Jens Bedke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Bedke. The network helps show where Jens Bedke may publish in the future.
Co-authors
The 25 scholars most cited alongside Jens Bedke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 309 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2019 | 2634 |
| 2 | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2019 | 1971 |
| 3 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2017 | 1377 |
| 4 | Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2021 | 1323 |
| 5 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Hit paper breakdown → | 2021 | 1323 |
| 6 | European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update Hit paper breakdown → | 2022 | 1008 |
| 7 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial Hit paper breakdown → | 2019 | 817 |
| 8 | Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Hit paper breakdown → | 2024 | 609 |
| 9 | Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2020 | 583 |
| 10 | Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma Hit paper breakdown → | 2021 | 547 |
| 11 | Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 488 |
| 12 | Economic aspects of bladder cancer: what are the benefits and costs? Hit paper breakdown → | 2009 | 399 |
| 13 | Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma Hit paper breakdown → | 2023 | 331 |
| 14 | Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2021 | 319 |
| 15 | Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial Hit paper breakdown → | 2022 | 228 |
| 16 | Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2022 | 210 |
| 17 | 2016 | 179 | |
| 18 | 2016 | 161 | |
| 19 | Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance Hit paper breakdown → | 2022 | 153 |
| 20 | 2021 | 124 |
About Jens Bedke
Jens Bedke is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research and Molecular Biology, having authored 309 papers that have together received 19.9k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (105 papers), Bladder and Urothelial Cancer Treatments (64 papers), Cancer Immunotherapy and Biomarkers (40 papers), Renal and related cancers (32 papers), Cancer Genomics and Diagnostics (25 papers), Prostate Cancer Diagnosis and Treatment (24 papers), Urinary and Genital Oncology Studies (16 papers) and Prostate Cancer Treatment and Research (14 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (9.5k citations), Oncology (6.3k citations), Cancer Research (2.6k citations), Surgery (4.9k citations) and Immunology (1.6k citations). Jens Bedke has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Arnulf Stenzl, Stephan Kruck, Jörg Hennenlotter, Thomas Powles, Steffen Rausch, Elizabeth R. Plimack, Axel Bex, Bastian Amend, Laurence K. Albiges and Tobias Klatte. Their work appears in journals such as World Journal of Urology, Annals of Oncology, European Urology, British Journal of Urology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.